Skip to content

A study to understand the pattern and treatment outcomes of bile duct cancer among patients registered at a tertiary care centre.

IDH1 Biliary Tract Cancer (BTC) Registry - BTC registry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/10/095713
Enrollment
200000
Registered
2025-10-08
Start date
Unknown
Completion date
Unknown
Last updated
2025-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C22- Malignant neoplasm of liver and intrahepatic bile ducts

Interventions

Intervention1: Nil: Nil

Sponsors

Vedanta Medical Research Foundation
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The study will include histopathologically confirmed metastatic Biliary tract cancer patients, who were undergoing treatment or at follow-up visit to the hospital during the study period. All adult patients who are aged 18 and above with biliary tract cancer and are willing to participate in the study.

Exclusion criteria

Exclusion criteria: Patients who are below 18 years and are not willing to participate.

Design outcomes

Primary

MeasureTime frame
To describe the profile and patterns of Biliary Tract cancer in patients availing of care at the reporting hospital. Timepoint: This is an observational study without any intervention. Data will be assessed for all registered patients during two time periods: 1)Retrospective phase: March 2018 to September 2025 2)Prospective phase: October 2025 to June 2027

Secondary

MeasureTime frame
Screen eligible patients & abstract medical records to describe the diagnostic, staging, & treatment details of Biliary Tract cancer patients.Timepoint: 24 Weeks

Countries

India

Contacts

Public ContactBhawna Sirohi

Vedanta Medical Research Foundation (BALCO Medical Centre)

bhawna.sirohi@vedanta.co.in9756999976

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026